Oxford vaccine shows 90% efficacy in Phase-3 trial — Science Chronicle

Interim data analysis of Phase-3 trial of Oxford/AstraZeneca COVID-19 candidate vaccine (ChAdOx1 nCoV-2019) showed different efficacies in preventing COVID-19 disease. In the case of the regimen where a halved dose was used as a prime (first dose) followed by a standard dose of booster, the efficacy was 90%. However, when full doses (standard doses) were […]

Oxford vaccine shows 90% efficacy in Phase-3 trial — Science Chronicle

Oxford vaccine found safe and immunogenic in Phase 2 Trial Results— Science Chronicle

Results of the Phase-2 trial of the Oxford vaccine show that the vaccine is safe across age groups — younger (18-55 years age) and older adults (over 56 years age). In fact, older adults better tolerated the vaccine than younger adults, the results show. The vaccine also induced T cell immune responses and neutralising antibodies […]

Oxford vaccine found safe and immunogenic even in older adults — Science Chronicle